

METHODS IN PHARMACOLOGY AND TOXICOLOGY

Series Editor
Y. James Kang
University of Louisville
School of Medicine
Prospect, Kentucky, USA



Dear MyCopy Customer,

This printed, personal Springer eBook is a unique service that is available at a low cost, only on link.springer.com because your library purchased at least one Springer eBook subject collection. This book is an exact, monochrome copy of the eBook on SpringerLink.

MyCopy books are strictly for individual use only, and not available for resale. You can cite this book by referencing the bibliographic data and/or the DOI (Digital Object Identifier) found in the front matter.

MyCopy is the ideal format for anyone who wants a physical copy for page-by-page study.

My Book, MyCopy.
Enjoy reading.

For further volumes:
<http://www.springer.com/series/7653>

Stem Cell-Derived Models in Toxicology

Edited by

Mike Clements

Axion BioSystems, Inc., Atlanta, GA, USA

Liz Roquemore

Cell Applications, GE Healthcare, Cardiff, UK

 **Humana Press**

Editors

Mike Clements
Axion BioSystems, Inc.
Atlanta, GA, USA

Liz Roquemoire
Cell Applications
GE Healthcare
Cardiff, UK

Videos can also be accessed at <http://link.springer.com/book/10.1007/978-1-4939-6661-5>

ISSN 1557-2153 ISSN 1940-6053 (electronic)
Methods in Pharmacology and Toxicology

DOI 10.1007/978-1-4939-6661-5

© Springer Science+Business Media New York 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Cover Illustration: Confocal microscopy image of a spheroid microtissue of hiPSC-derived cardiomyocytes (Cellular Dynamics International, Madison, USA) and human umbilical vein endothelial cells (Zen-Bio Inc., Durham, USA) produced using the GravityTrap hanging drop method (InSphero AG, Schlieren, Switzerland), and immunostained for von Willebrand factor (green), sarcomeric protein myomesin (red), and DNA (blue); from Chapter 11, Zuppinger. Overlaid is a field potential transient signal recorded from spontaneously beating hSC-derived cardiomyocytes on the multielectrode array (MEA) platform (Axion BioSystems Inc., Atlanta, USA); from Preface, Clements.

Printed on acid-free paper

This Humana Press imprint is published by Springer Nature

The registered company is Springer Science+Business Media LLC

The registered company address is: 233 Spring Street, New York, NY 10013, U.S.A.

Preface

Unexpected adverse toxicity findings in drug development or postlaunch have resulted in numerous costly late-stage drug development failures and market withdrawals. To mitigate this risk, the pharmaceutical industry has adopted a range of assays to probe the liability of compounds earlier in the drug development process consistent with the mantra “fail faster, fail cheaper”. In the drug discovery process, lead optimization is the ideal phase to screen for safety issues, since at this point failure is relatively cheap and the number of potential compounds for selection (~1000) is greatest. The currently available standard testing models include primary tissue and immortalized cell lines. While immortalized cell lines lend themselves to screening applications (e.g. relatively inexpensive, abundant, easy to handle), the assay end point can be overly simplistic, leading to false positives (i.e. compounds flagged as toxic which are in fact safe) and false negatives (i.e. compounds misidentified as safe when actually toxic). Primary tissue (typically rodent) is often useful for small investigative studies but is not applicable for screening applications, due to both cost and ethical concerns with regard to animal consumption (3Rs). Concerns also persist with the translation of this data to humans due to possible species differences. Consequently, there is increasing demand for more relevant and predictive nonclinical models for in vitro toxicity testing (see Chap. 1, Gintant and Braam).

AU1

Since the first descriptions of the differentiation of cardiomyocytes from human embryonic stem cells (hESC) more than a decade ago, there has been much speculation over the utility of these cells for drug safety assessment [1]. Human ESC and human-induced pluripotent stem cell-derived (hiPSC) models, together termed human stem cell-derived (hSC) models, offer an opportunity to provide a more predictive, integrated human model system that is amenable to high-throughput screening in preclinical drug safety assessment. The relative immaturity of these stem cell-derived models is well documented (e.g. [2]), which has led some to question the applicability of hSC-derived models in toxicological studies (i.e. “they are not old enough for drugs”).

AU2

Although methods to produce hSC-derived models with more “adultlike” phenotypes are currently the focus of intensive research efforts, there is considerable data in the literature to suggest a role for the current iteration of this technology. Accordingly, the potential application of hSC-cardiomyocytes (hSC-CMs) in advancing the development of more predictive preclinical cardiac safety assessment is now the subject of extended testing in the regulatory communities. This includes proposals such as the Japan iPS Cardiac Safety Assessment (JiCSA) consortium with the objective to validate hiPSC-CM assay for regulatory purposes and HESI’s Comprehensive in vitro Proarrhythmia Assay (CiPA) which aims to obviate the need for clinical QT studies. The core components of CiPA will include a mathematical (i.e. in silico) model of cardiac muscle electrical activity based on in vitro ion channel data to predict whether new drugs will cause dangerous changes to heart rhythm (i.e. proarrhythmia). A complementary in vitro hSC-CM assay will be integrated into this process with the aim of confirming or casting doubt on the in silico predictions and to broaden the cardiac safety assessment of the candidate drug to include additional proarrhythmic mechanisms not discoverable by the in silico analysis. This is a very promising development for the acceptance

of hSC-derived models in drug discovery and toxicology, and with increased characterization of these hSC-derived models and validation of their associated assays, they will surely grow in prominence.

The majority of this book is focused on differentiated tissues, but we begin the protocol chapters with a high-throughput screen designed to predict embryonic-foetal developmental toxicity using hESCs (Chap. 2, Kameoka and Chiao). One of the first applications of pluripotent stem cells in toxicology was the mouse embryonic stem cell test (mEST), which has been deemed of sufficient value for consideration in regulatory acceptance and submission documents. Here, Kameoka and Chiao describe an improved human embryonic stem cell test (hEST) thus avoiding the extrapolation of responses from animals to humans.

Over half of the chapters in this volume are focused on cardiotoxicity applications. The underlying reason for this bias towards hSC-CM assays is severalfold. Firstly, the cardiomyocyte differentiation process was one of the first to be characterized (hESC-CMs in 2003 and hiPSC-CMs in 2009) and can now be employed to manufacture these cells on an industrial scale suitable for screening applications. Secondly, a human primary model is not readily available (e.g. unlike for hSC-hepatocytes), so there is a large unmet need from the cardiotoxic field. Thirdly, the hSC-CM model has been demonstrated to add value over and above existing model systems (e.g. the antihistamine, terfenadine, produces the expected prolongation of the cardiac action potential in hSC-CMs at clinical relevant concentrations, unlike the false-negative result observed in both canine and porcine Purkinje fibres even at supra-therapeutic concentrations). Finally, cardiotoxicity is one of the most prevalent forms of drug-induced toxicity. Although the recent regulatory guidelines have been successful in reducing the release of proarrhythmic drugs coming to market, there is a general consensus that the extensive focus on a single ion channel (hERG K⁺ channel) has resulted in an overly high attrition rate (false positives) in drug development, prematurely halting the development of otherwise promising candidate drugs. CiPA proposes that safety studies using multiple ion channel effects (MICE) models, such as hSC-CMs, are likely to be more predictive of clinical drug response where compensatory drug actions on one or more other ion channels mitigate the effects due to hERG blockade.

Manual patch-clamp remains the “gold-standard” for probing drug-induced cardiac ion channel effects (see Chap. 3, Renganathan et al.), and an automated method for increasing assay throughput is also described here (Chap. 4, Obergrussberger et al.). However, manual patch-clamp is very labour intensive, and the difficulties translating automated patch-clamp protocols to hSC-derived models have resulted in the CiPA initiative focusing on analogous emerging electrophysiology-based technologies, namely, multi-electrode array (MEA; see Chap. 5, Millard et al., and Chap. 10 Obergrussberger et al.) and voltage-sensitive optical probes (i.e. genetically encoded voltage indicators, GEVIs (see Chap. 6, Dempsey et al.), and voltage-sensitive dyes, VSDs (see Chap. 7, Kettenhofen)). These techniques present their own strengths and limitations as discussed in the relevant chapters.

Not all cardiotoxicity can be observed by changes in hSC-CM excitability with the aforementioned electrophysiology-based assays. Full and efficient assessment of new drug development liabilities must take a holistic account of both the structural and functional aspects of cell biology. The relative complexity of stem cell-derived models makes them applicable to surveying a wide range of mechanisms whereby a new chemical entity may perturb cell function. Accordingly, this has sparked the development of a diverse range of innovative analytical platforms with the potential to probe previously inaccessible features of cell function (Fig. 1).

Cardiomyocyte excitability (i.e. an action potential) initiates calcium release into the cell and is subsequently removed from the cytoplasm prior to the next contraction event.




Fig. 1 One cell to bind them all: bridging analytical platforms. As well as providing a more relevant nonclinical model for in vitro toxicity testing, hSC-derived models have the potential to bridge analytical platforms and in doing so provide an integrated model for probing many possible causes and mechanisms of toxicity. The example of hSC-cardiomyocytes (*centre*) and some of the possible associated assays are illustrated here

Compound-induced effects on these calcium transients can be measured with high-throughput calcium imaging platforms as either the mean response of the hSC-CM monolayer (see Chap. 7, Kettenhofen) or with single-cell resolution (see Chap. 8, Pfeiffer et al., and Chap. 9, George et al.). In turn, this calcium signal is converted into the mechanical contraction of the cardiomyocyte. The physical movement of a layer of beating cardiomyocytes can be continuously monitored with the impedance assay (see Chap. 10, Obergrussberger et al.) or image-based edge detection of a beating spheroid (see Chap. 11, Zuppinger et al.). Measuring this downstream hSC-CM movement can be advantageous since compounds can perturb the cell's contractile machinery, without impacting its electrophysiology, e.g. the myosin II inhibitor blebbistatin. These platforms, however, do not measure the direct force of contraction, which would be advantageous when screening for unwanted compound-induced changes to the strength of cardiac contractility (i.e. inotropic effects). This requirement is addressed in Chap. 12 (Oleaga et al.), where a novel micro-cantilever-based device is employed to detect perturbations in the force of hSC-CM contractions.

In addition to altering the acute mechanical function of the heart (functional toxicity), cardiotoxicity can also occur due to morphological damage to cardiomyocytes, damage to intracellular organelles, or loss of cardiomyocyte viability (structural toxicity), resulting in cardiomyopathy and heart failure. Methods for screening for compound-induced changes to cell morphology are described in Chap. 13 (Roquemoire et al., high-content image analysis, HCA) and Chap. 14 (Kriston-Vizi et al., hypertrophy).

Human SC-neurons similarly offer a novel method of screening for neurotoxins. The MEA assay can be employed to predict neurotoxic risk associated with drugs or compounds present in the environment by monitoring subtle perturbations to the spontaneous firing patterns of hSC-neuronal cultures (e.g. insecticides; see Chap. 15, Kraushaar et al.).

Hepatotoxicity is a major cause of drug attrition, and consequently, in vitro liver-based assays are an integral part of preclinical safety assessments. Primary human hepatocytes are currently the model of choice but are limited by donor-to-donor variability and the short period of time they are functional in culture (i.e. they are unsuitable for assessing the effects of prolonged compound exposure). Human SC-hepatocytes could potentially address these concerns, but their implementation in toxicity assays has been hindered largely due to difficulties in obtaining a mature metabolic phenotype. The expression of CYP3A4, the most abundant cytochrome P450 in the liver, is expressed at lower levels in hSC-hepatocytes compared with primary human hepatocytes. This is of concern since CYP450-dependent formation of toxic metabolites is a cause of drug-induced liver injury. That said, promising hSC-hepatocyte data has emerged from methods attempting to replicate the cellular micro-structure of the liver (see Chap. 16, Ware and Khetani).

With the first commercially available hSC-derived models, there was an initial drive to produce >95% “pure” cell models. The rationale behind this approach was that it would be preferable if drug-induced effects observed in biochemical assays could be assigned to a single-cell type. However, recent findings suggest that the presence of stromal (e.g. fibroblast) cells in the culture of interest adds functionality and ultimately increases predictivity. The precise mixing of different highly pure cell types with stromal cells now allows the end user to titrate the performance of the model to achieve the desired functionality (see Chap. 11, Zuppinger, for hSC-CMs; and Chap. 16, Ware and Khetani, for hSC-hepatocytes). The advent of technologies that facilitate self-assembling 3D spheroids and self-ordering patterns of cells in 2D culture has helped limit the inevitable increase in assay set-up time and cost associated with the added complexity of these co-culture models.

For the first time, this volume brings together a diverse collection of stem cell-derived model-based toxicity assays, from those routinely used to those deemed to have considerable potential. Key opinion leaders from academia and industry have been invited to contribute their preferred assay protocols with accompanying rationale and example output data. Our goal is to enable adoption of these protocols in laboratories that are interested in entering the field as well as to facilitate the transfer of best practices between laboratories that are already actively pursuing these technologies. The use of stem cell-derived models in safety pharmacology and toxicology is in their infancy, but their potential for improving risk assessment will inevitably drive the development of even more innovative methods to probe toxicity.

AU3

Atlanta, GA, USA
Cardiff, UK

Mike Clements
Liz Roquemore

References

1. Davila JC, Cezar GG, Thiede M, Strom S, Miki T, Trosko J (2004) Use and application of stem cells in toxicology. *Toxicol Sci* 79(2):214–223
2. Veerman CC, Kosmidis G, Mummery CL, Casini S, Verkerk AO, Bellin M (2015) Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? *Stem Cells Dev* 24(9):1035–1052

Contents

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>xi</i>
1 Stem Cell-Derived Models for Safety and Toxicity Assessments: Present and Future Studies in the “Proclinical Space”	1
<i>Gary Gintant and Stefan Braam</i>	
2 Human Pluripotent Stem Cell Test for Assessing the Potential Teratogen Risk	17
<i>Sei Kameoka and Eric Chiao</i>	
3 Cardiac Action Potential Measurement in Human Embryonic Stem Cell Cardiomyocytes for Cardiac Safety Studies Using Manual Patch-Clamp Electrophysiology	37
<i>Muthukrishnan Renganathan, Haiyang Wei, and Yong Zhao</i>	
4 Automated Patch Clamp Recordings of Human Stem Cell-Derived Cardiomyocytes	57
<i>Alison Obergrussberger, Claudia Haarmann, Sonja Stölzle-Feix, Nadine Becker, Atsushi Ohtsuki, Andrea Brüggemann, Michael George, and Niels Fertig</i>	
5 The CiPA Microelectrode Array Assay with hSC-Derived Cardiomyocytes: Current Protocol, Future Potential.	83
<i>Daniel C. Millard, Mike Clements, and James D. Ross</i>	
6 Optogenetic Approach to Cardiotoxicity Screening: Simultaneous Voltage and Calcium Imaging Under Paced Conditions.	109
<i>Graham T. Dempsey and Christopher A. Werley</i>	
7 HTS-Compatible Voltage- and Ca^{2+} -Sensitive Dye Recordings from hiPSC-Derived Cardiomyocytes Using the Hamamatsu FDSS Systems	135
<i>Ralf Kettenhofen</i>	
8 Kinetic Image Cytometry for Predicting Arrhythmias Using Human Stem Cell-Derived Cardiomyocytes	153
<i>Emily R. Pfeiffer, Ross Whittaker, Raquel Vega, Fabio Cerignoli, Patrick M. McDonough, and Jeffrey H. Price</i>	
9 Decoding Ca^{2+} Signals as a Non-electrophysiological Method for Assessing Drug Toxicity in Stem Cell-Derived Cardiomyocytes	173
<i>Christopher H. George and David H. Edwards</i>	
10 Combined Impedance and Extracellular Field Potential Recordings from Human Stem Cell-Derived Cardiomyocytes	191
<i>Alison Obergrussberger, Ulrich Thomas, Sonja Stölzle-Feix, Nadine Becker, Krisztina Juhasz, Leo Doerr, Matthias Beckler, Michael George, and Niels Fertig</i>	

11	Edge-Detection for Contractility Measurements with Cardiac Spheroids	211
	<i>Christian Zuppinger</i>	
12	Contractile Force Readout of hESC-Cardiomyocytes	229
	<i>Carlota Oleaga, Gregg Legters, L. Richard Bridges, Lee Kumanchik, Candace Martin, Yunqing Cai, Mark Schnepfer, Christopher W. McAleer, Christopher J. Long, and James J. Hickman</i>	
13	In Vitro Cardiotoxicity Investigation Using High Content Analysis and Human Stem Cell-Derived Models.	247
	<i>Liz Roquemore, M. Ariel Kauss, Catherine Hather, Nick Thomas, and Hirdesh Uppal</i>	
14	Structural Toxicity: Hypertrophy Models of Human Pluripotent Stem Cell-Derived Cardiomyocytes.	271
	<i>Janos Kriston-Vizi, Sian E. Harding, and Gábor Földes</i>	
15	Addressing Functional Neurotoxicity Using the Microelectrode Array (MEA)	293
	<i>Udo Kraushaar, Elke Guenther, and Dietmar Hess</i>	
16	Micropatterned Co-Cultures of Induced Pluripotent Stem Cell-Derived Hepatocytes and Stromal Cells for Drug Toxicity Studies	311
	<i>Brenton R. Ware and Salman R. Khetani</i>	
	<i>Index</i>	335

Contributors

- AU4 NADINE BECKER • *Nanon Technologies GmbH, Munich, Germany*
MATTHIAS BECKLER • *Nanon Technologies GmbH, Munich, Germany*
ANDREA BRÜGGEMANN • *Nanon Technologies GmbH, Munich, Germany*
STEFAN BRAAM • *Pluriomics BV, BD Leiden, The Netherlands*
L. RICHARD BRIDGES • *NanoScience Technology Center, University of Central Florida, Orlando, FL, USA*
YUNQING CAI • *NanoScience Technology Center, University of Central Florida, Orlando, FL, USA*
FABIO CERIGNOLI • *Vala Sciences, San Diego, CA, USA*
ERIC CHIAO • *Regeneron Pharmaceuticals, Tarrytown, NY, USA*
MIKE CLEMENTS • *Axion BioSystems, Inc., Atlanta, GA, USA*
GRAHAM T. DEMPSEY • *Q-State Biosciences, Cambridge, MA, USA*
LEO DOERR • *Nanon Technologies GmbH, Munich, Germany*
DAVID H. EDWARDS • *School of Medicine, Cardiff University, Cardiff, UK*
GÁBOR FÖLDES • *National Heart and Lung Institute, Imperial Centre for Experimental and Translational Medicine, Imperial College London, London, UK; Heart and Vascular Center, Semmelweis University, Budapest, Hungary*
NIELS FERTIG • *Nanon Technologies GmbH, Munich, Germany*
MICHAEL GEORGE • *Nanon Technologies GmbH, Munich, Germany*
CHRISTOPHER H. GEORGE • *School of Medicine, Cardiff University, Cardiff, UK*
GARY GINTANT • *AbbVie, Integrative Pharm., Integrated Science and Technology, North Chicago, IL, USA*
ELKE GUENTHER • *Department of Electrophysiology, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany*
CLAUDIA HAARMANN • *Nanon Technologies GmbH, Munich, Germany*
SIAN E. HARDING • *National Heart and Lung Institute, Imperial Centre for Experimental and Translational Medicine, Imperial College London, London, UK*
CATHERINE HATHER • *GE Healthcare, Cardiff, UK*
DIETMAR HESS • *Axiogenesis AG, Cologne, Germany*
JAMES J. HICKMAN • *NanoScience Technology Center, University of Central Florida, Orlando, FL, USA*
KRISZTINA JUHASZ • *Nanon Technologies GmbH, Munich, Germany*
SEI KAMEOKA • *Vertex Pharmaceuticals, Boston, MA, USA*
M. ARIEL KAUSS • *University of California at San Francisco, San Francisco, CA, USA*
RALF KETTENHOFEN • *Axiogenesis AG, Cologne, Germany*
SALMAN R. KHETANI • *School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA; Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, USA; Department of Mechanical Engineering, Colorado State University, Fort Collins, CO, USA*

- UDO KRAUSHAAR • *Department of Electrophysiology, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany*
- JANOS KRISTON-VIZI • *MRC Laboratory for Molecular Cell Biology, University College London, London, UK*
- LEE KUMANCHIK • *NanoScience Technology Center, University of Central Florida, Orlando, FL, USA*
- GREGG LEGTERS • *NanoScience Technology Center, University of Central Florida, Orlando, FL, USA*
- CHRISTOPHER J. LONG • *NanoScience Technology Center, University of Central Florida, Orlando, FL, USA*
- CANDACE MARTIN • *NanoScience Technology Center, University of Central Florida, Orlando, FL, USA*
- CHRISTOPHER W. McALEER • *NanoScience Technology Center, University of Central Florida, Orlando, FL, USA*
- PATRICK M. McDONOUGH • *Vala Sciences, San Diego, CA, USA*
- DANIEL C. MILLARD • *Axion BioSystems, Inc., Atlanta, GA, USA*
- ALISON OBERGRUSSBERGER • *Nanion Technologies GmbH, Munich, Germany*
- ATSUSHI OHTSUKI • *Nanion Technologies GmbH, Tokyo Laboratory, Medical Innovation Laboratory, Tokyo Women's Medical University and Waseda University Joint Institution for Advanced Biomedical Sciences, Tokyo, Japan*
- CARLOTA OLEAGA • *NanoScience Technology Center, University of Central Florida, Orlando, FL, USA*
- EMILY R. PFEIFFER • *Vala Sciences, San Diego, CA, USA*
- JEFFREY H. PRICE • *Vala Sciences, San Diego, CA, USA*
- MUTHUKRISHNAN RENGANATHAN • *Eurofins Pharma Inc., St Charles, MO, USA*
- LIZ ROQUEMORE • *GE Healthcare, Cardiff, UK*
- JAMES D. ROSS • *Axion BioSystems, Inc., Atlanta, GA, USA*
- MARK SCHNEPPER • *NanoScience Technology Center, University of Central Florida, Orlando, FL, USA*
- SONJA STÖLZLE-FEIX • *Nanion Technologies GmbH, Munich, Germany*
- ULRICH THOMAS • *Nanion Technologies GmbH, Munich, Germany*
- NICK THOMAS • *GE Healthcare, Cardiff, UK*
- HIRDESH UPPAL • *Medivation Inc., San Francisco, CA, USA*
- RAQUEL VEGA • *Vala Sciences, San Diego, CA, USA*
- BRENTON R. WARE • *School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA; Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, USA*
- HAIYANG WEI • *Eurofins Pharma Inc., St Charles, MO, USA*
- CHRISTOPHER A. WERLEY • *Q-State Biosciences, Cambridge, MA, USA*
- ROSS WHITTAKER • *Vala Sciences, San Diego, CA, USA*
- YONG ZHAO • *Eurofins Pharma Inc., St Charles, MO, USA*
- CHRISTIAN ZUPPINGER • *Cardiology, Department of Clinical Research MEM G803b, Bern University Hospital, Bern, Switzerland*

Author Queries

Chapter No.: FM 0002838355

Queries	Details Required	Author's Response
AU1	Both “immortalized cell lines” and “immortal cell lines” have been used in text. Please check if one form should be made consistent.	
AU2	Please note that reference citations have been changed from NameYear to Numbered as per the style.	
AU3	Please check whether the signature line of the editors are appropriate as typeset.	
AU4	Please check whether the contributed author names and their institutional details are appropriate as typeset.	

Stem Cell-Derived Models in Toxicology

Clements, M.; Roquemore, L. (Eds.)

2017, XII, 341 p. 124 illus., 108 illus. in color. With

online files/update., Hardcover

ISBN: 978-1-4939-6659-2

A product of Humana Press